AR057703A1 - INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS. - Google Patents

INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS.

Info

Publication number
AR057703A1
AR057703A1 ARP060103309A AR057703A1 AR 057703 A1 AR057703 A1 AR 057703A1 AR P060103309 A ARP060103309 A AR P060103309A AR 057703 A1 AR057703 A1 AR 057703A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkoxy
cycloalkyl
group
Prior art date
Application number
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd, Medivir Ab filed Critical Tibotec Pharm Ltd
Publication of AR057703A1 publication Critical patent/AR057703A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Reivindicacion 1: Un compuesto que tiene la formula (1) un N-oxido, sal, o estereoisomero de éste, donde cada línea de puntos (representada por -----) representa un doble enlace opcional; X es N, CH y cuando X lleva un doble enlace es C; R1 es -OR6, -NH-SO2R7; R2 es hidrogeno, y cuando X es C o CH, R2 también puede ser alquilo C1-6; R3 es hidrogeno, alquilo C1-6, alcoxi C1-6alquilo C1-6, o cicloalquilo C3-7; n es 3, 4, 5, o 6; R4 y R5 tomados junto con el atomo de nitrogeno al cual están unidos forman un sistema anular bicíclico seleccionado del grupo de formulas (2) donde dicho sistema anular puede estar sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados en forma independiente de halo, hidroxi, oxo, nitro, ciano, carboxilo, alquilo C1-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, amino, azido, mercapto, polihaloalquiloC1-6; R6 es hidrogeno; arilo; Het; cicloalquilo C3-7 sustituido en forma opcional con alquilo C1-6; o alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo o con Het; R7 es arilo; Het; cicloalquilo C3-7 sustituido en forma opcional con alquilo C1-6; o alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo o con Het; arilo como grupo o parte de un grupo es fenilo o naftilo, cada uno de los cuales puede estar sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados de halo, hidroxi, nitro, ciano, carboxilo, alquilo C1-6, alcoxi C1-6, alcoxi C1- 6-alquilo C1-6, alquilcarbonilo, C1-6, amino, mono- o dialquilamino C1-6, azido, mercapto, polihaloalquilo C1-6, polihaloalcoxi C1-6, cicloalquilo C3-7, pirrolidinilo, piperidinilo, piperazinilo, 4-alquil C1-6-piperazinilo, 4-alquilcarbonil C1-6- piperazinilo, y morfolinilo; donde los grupos morfolinilo y piperidinilo pueden estar sustituidos en forma opcional con uno o dos radicales alquilo C1-6; Het como grupo o parte de un grupo es un anillo heterocíclico saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros que contiene 1 a 4 heteroátomos seleccionado cada uno en forma independiente de nitrogeno, oxígeno y azufre, y sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados, cada uno en forma independiente, del grupo que consiste en halo, hidroxi, nitro, ciano, carboxilo, alquilo C1-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6, alquilcarbonilo C1-6, amino, mono- o di-alquilamino C1-6, azido, mercapto, polihaloalquilo C1-6, polihaloalcoxi C1-6, cicloalquilo C3-7, pirrolidinilo, piperidinilo, pieprazinilo, 4-alquil C1-6-piperazinilo, 4-alquilcarbonil C1-6-piperazinilo, y morfolinilo; donde los grupos morfolinilo y piperidinilo pueden estar sustituidos en forma opcional con uno o dos radicales alquilo C1-6. Composiciones farmacéuticas que contienen compuestos (I) y procesos para preparar los compuestos (I). También se proporcionan combinaciones biodisponibles de los inhibidores del VHC de formula (I) con ritonavir.
ARP060103309 2005-07-29 2006-07-28 INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS. AR057703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107071 2005-07-29

Publications (1)

Publication Number Publication Date
AR057703A1 true AR057703A1 (es) 2007-12-12

Family

ID=35589621

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103309 AR057703A1 (es) 2005-07-29 2006-07-28 INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS.

Country Status (19)

Country Link
US (1) US9023808B2 (es)
EP (1) EP1919899B1 (es)
JP (1) JP5230415B2 (es)
KR (1) KR101381176B1 (es)
CN (1) CN101273028B (es)
AR (1) AR057703A1 (es)
AT (1) ATE496042T1 (es)
AU (1) AU2006274862B2 (es)
BR (1) BRPI0614620A2 (es)
CA (1) CA2617099C (es)
DE (1) DE602006019741D1 (es)
DK (1) DK1919899T3 (es)
EA (1) EA013475B1 (es)
ES (1) ES2359939T3 (es)
MY (1) MY141245A (es)
PL (1) PL1919899T3 (es)
SI (1) SI1919899T1 (es)
TW (1) TWI382025B (es)
WO (1) WO2007014923A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR101159575B1 (ko) 2004-01-30 2012-07-06 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ―３ 세린 프로테아제 저해제
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PL1913015T3 (pl) 2005-07-29 2014-04-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
EP2111396B1 (en) * 2007-02-08 2013-08-07 Janssen R&D Ireland Hcv inhibiting macrocyclic phenylcarbamates
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009117594A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010218152B2 (en) * 2009-02-27 2015-04-09 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of Dengue virus infections
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
AU2011229164B2 (en) * 2010-03-16 2015-11-26 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659575B2 (en) 1992-12-29 1995-05-18 Abbvie Inc. Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharma Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
KR100940619B1 (ko) 2003-02-07 2010-02-05 이난타 파마슈티칼스, 인코포레이티드 마크로사이클릭 씨형 간염 세린 단백효소 억제제
EP1629000B1 (en) * 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
US7642235B2 (en) * 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ES2398912T3 (es) * 2003-10-14 2013-03-22 F. Hoffmann-La Roche Ltd. Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
KR101159575B1 (ko) * 2004-01-30 2012-07-06 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ―３ 세린 프로테아제 저해제
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2437886C2 (ru) * 2005-07-29 2011-12-27 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
US7700552B2 (en) * 2005-07-29 2010-04-20 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
DK1912996T3 (da) * 2005-07-29 2012-09-17 Janssen R & D Ireland Makrocykliske inhibitorer af hepatitis C-virus
WO2008134395A1 (en) * 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
PL1919899T3 (pl) 2011-06-30
SI1919899T1 (sl) 2011-05-31
AU2006274862A1 (en) 2007-02-08
EP1919899A1 (en) 2008-05-14
US9023808B2 (en) 2015-05-05
CA2617099C (en) 2014-03-25
US20090247512A1 (en) 2009-10-01
EA200800478A1 (ru) 2008-08-29
JP5230415B2 (ja) 2013-07-10
EA013475B1 (ru) 2010-04-30
DK1919899T3 (da) 2011-08-01
WO2007014923A1 (en) 2007-02-08
KR20080039422A (ko) 2008-05-07
JP2009502886A (ja) 2009-01-29
ATE496042T1 (de) 2011-02-15
TW200800949A (en) 2008-01-01
AU2006274862B2 (en) 2012-03-22
MY141245A (en) 2010-03-31
CA2617099A1 (en) 2007-02-08
BRPI0614620A2 (pt) 2011-04-12
TWI382025B (zh) 2013-01-11
EP1919899B1 (en) 2011-01-19
DE602006019741D1 (de) 2011-03-03
ES2359939T3 (es) 2011-05-30
CN101273028A (zh) 2008-09-24
KR101381176B1 (ko) 2014-04-11
CN101273028B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
AR057703A1 (es) INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS.
AR057704A1 (es) Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto
AR055361A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR055104A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR054882A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR055105A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR055359A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR074758A1 (es) Compuestos macrociclicos antivirales
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CO2017003132A2 (es) Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
CO6180506A2 (es) Inhibidores de la proteasa ns3 del hcv
AR069740A1 (es) Compuestos nucleosidos antivirales
AR044956A1 (es) Derivados de pirrolodihidroisoquinolinas, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer.
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
NI201000011A (es) Derivados de pirimidina 934.
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
AR066154A1 (es) Derivados de piperidina / piperazina
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia

Legal Events

Date Code Title Description
FB Suspension of granting procedure